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Acute invariant NKT cell activation 
triggers an immune response 
that drives prominent changes 
in iron homeostasis
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Manon Oliero1,4, Geneviève Chabot‑Roy5, Victor Mullins‑Dansereau1,4, Sylvie Lesage4,5 & 
Manuela M. Santos1,2,6*
Iron homeostasis is an essential biological process that ensures the tissue distribution of iron for 
various cellular processes. As the major producer of hepcidin, the liver is central to the regulation of 
iron metabolism. The liver is also home to many immune cells, which upon activation may greatly 
impact iron metabolism. Here, we focus on the role of invariant natural killer T (iNKT) cells, a subset 
of T lymphocytes that, in mice, is most abundant in the liver. Activation of iNKT cells with the 
prototypical glycosphingolipid antigen, α‑galactosylceramide, resulted in immune cell proliferation 
and biphasic changes in iron metabolism. This involved an early phase characterized by hypoferremia, 
hepcidin induction and ferroportin suppression, and a second phase associated with strong 
suppression of hepcidin despite elevated levels of circulating and tissue iron. We further show that 
these changes in iron metabolism are fully dependent on iNKT cell activation. Finally, we demonstrate 
that the biphasic regulation of hepcidin is independent of NK and Kupffer cells, and is initially driven 
by the STAT3 inflammatory pathway, whereas the second phase is regulated by repression of the 
BMP/SMAD signaling pathway. These findings indicate that iNKT activation and the resulting cell 
proliferation influence iron homeostasis.
Anaemia of chronic disease (ACD) or anaemia of inflammation is the second most prevalent cause of anaemia, 
after iron deficiency  anaemia1. ACD is driven by the activation of immune cells and their production of inflam-
matory  cytokines1. Hallmarks of ACD include disturbances in iron homeostasis that divert iron from the circula-
tion into storage sites, thereby reducing iron availability for  erythropoiesis2. Disrupted iron homeostasis in ACD 
is achieved via the regulation of genes involved in cellular iron uptake and export, and leads to increased uptake 
and retention of iron within cells of the reticuloendothelial system. Specifically, tumour necrosis factor alpha 
(TNF-α), interleukin (IL)-1, IL-6, and interferon gamma (IFN-γ) are cytokines that can directly modulate the 
translation/transcription of genes involved in iron homeostasis, such as the iron-regulatory hormone hepcidin 
in the  liver3. The main cell types that produce these cytokines include T lymphocytes and macrophages, and 
their activation contributes to  ACD1,4.
The liver is the major regulator of systemic iron homeostasis through hepcidin  production5,6 and is home 
to many immune cell  types7, including conventional and non-conventional T  cells8. In mice, invariant natural 
killer T (iNKT) cells are most abundant in the liver. These iNKT cells express T cell receptors (TCR) that rec-
ognize lipid or glycolipid antigens presented by the MHC class I-related glycoprotein  CD1d9,10. In the absence 
of effective lipid presentation by CD1d, iNKT cells accumulate in the liver and contribute to  inflammation11. 
However, in the presence of obesity, presentation of endogenous lipids to iNKT cells in the liver also contributes 
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to  inflammation12. Indeed, activated iNKT cells rapidly secrete both Th1- and Th2-type  cytokines13, which facili-
tates the recruitment and activation of many other immune cells, such as NK cells, myeloid cells, and various T 
cell subsets, to stimulate anti-tumor immune  responses14,15. As such, the release of large amounts of cytokines 
by activated iNKT  cells13 may potentially affect iron homeostasis by inducing hepcidin expression in the  liver16. 
Thus, iNKT cells represent a unique cell population that may influence iron metabolism.
Here, we investigated the influence of iNKT cell activation on iron metabolism. Our results indicate that 
iNKT cell activation induces profound alterations in iron homeostasis.
Results
Activation of iNKT cells in vivo with α‑GalCer induces changes in iron metabolism. The proto-
typical iNKT cell ligand, α-galactosylceramide (α-GalCer), induces a potent primary iNKT cell  response17. To 
evaluate the impact of acute iNKT cell activation on iron metabolism, we injected wild-type mice with α-GalCer 
and monitored the mice for six days. As expected, α-GalCer treatment led to a significant increase in liver and 
spleen weights, peaking at day 3 (Fig. 1A). This is in line with a robust iNKT cell activation, leading to immune 
cell recruitment and  proliferation18,19. iNKT cell activation also impacted iron metabolism. Total iron levels in 
the liver and spleen increased, mirroring the increase in liver and spleen weights (Fig. 1B). In contrast, circulat-
ing iron levels, which were assessed by measuring serum iron levels and transferrin saturation, decreased during 
the first 6 h following α-GalCer treatment and was followed by a significant increase between 24 and 48 h, with 
levels returning to normal by day 3 (Fig. 1C). In turn, hepcidin expression levels (Hamp) were elevated two-fold 
at 6 h after α-GalCer treatment, and then suppressed from 12 h and up to day 3 (Fig. 1D). Ferroportin 1 (Fp1) 
levels were rapidly suppressed starting at 3 h and up to 48 h after treatment (Fig. 1D). Overall, these data show 
that activation of iNKT cells by α-GalCer leads to biphasic changes in iron metabolism.
Figure 1.  Time course of α-GalCer-induced changes in systemic iron metabolism. Wild-type mice were 
injected with vehicle (indicated by the gray area across the graphs) or 100 μg/Kg body weight of α-GalCer. (A) 
Liver and spleen weights. (B) Total iron in liver and spleen. (C) Serum iron and transferrin saturation. (D) 
Hepcidin (Hamp) and ferroportin 1 (Fp1) mRNA expression. Data are presented as mean ± SEM for a minimum 
of n = 12 mice per time point. Statistical analysis was performed with one-way ANOVA. *(blue lines) and 
†(purple lines) P < 0.01, compared to mice injected with vehicle at each time point.
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Changes in iron metabolism induced by α‑GalCer depend on the presence of CD1d and iNKT 
cells. α-GalCer loaded onto CD1d specifically binds to and activates iNKT cells. Therefore, the changes 
in iron metabolism following in vivo α-GalCer treatment most likely resulted from iNKT cell activation. To 
determine if the changes in iron metabolism were a direct or indirect consequence of iNKT cell activation by 
α-GalCer presented by CD1d, we used CD1d-deficient mice (CD1d−/−), which lack both iNKT and type 2 NKT 
 cells20. After α-GalCer administration, CD1d−/− mice had no variations in liver weight, and serum iron and hep-
cidin levels in the liver remained unaffected at 6 h and at 24 h (Fig. 2). These results demonstrate that α-GalCer 
treatment induces changes in iron metabolism in a CD1d-dependent manner.
Next, to determine if the absence of changes in iron metabolism following α-GalCer treatment in CD1d−/− mice 
was either due to the absence of α-GalCer presentation by CD1d or due to the absence of NKT cells, we assessed 
the effect of α-GalCer on iron homeostasis using Jα18−/− mice. These mice are deficient for the Jα18 TCR segment 
and specifically lack Vα14 iNKT cells, whereas all the other lymphoid cell lineages, including type 2 NKT cells, 
are  intact21. The mice also express CD1d and are thus able to present α-GalCer. When compared to wild-type 
mice, liver weights in Jα18−/− mice remained unchanged at 24 h post α-GalCer-treatment (Fig. 3A). Moreover, 
serum iron (Fig. 3B) and hepcidin mRNA expression (Fig. 3C) remained unaltered at both 6 h and 24 h follow-
ing α-GalCer treatment. These results confirm that iNKT cells are indispensable for α-GalCer-induced changes 
in iron homeostasis and demonstrate that iNKT cell activation is sufficient to trigger prominent changes in iron 
homeostasis.
The impact of α‑GalCer on iron homeostasis is independent of NK cells. We demonstrated that 
iNKT cell activation with α-GalCer affects iron homeostasis. We then investigated other cellular downstream 
effectors that may contribute to the changes in iron homeostasis. Considering that changes in iron metabo-
lism occurred within hours of α-GalCer administration and that the changes did not persist beyond three days 
(Fig. 1), we examined the cellular components of innate immunity, such as NK cells, known to respond within 
this  timeframe15,22. We depleted NK cells using the anti-asialoGM1 (α-AGM1)  antibody23, which resulted in 
more than 75% depletion of NK cells in the liver (Supplementary Fig. 1). Two groups of mice, control isotype 
Ig-injected and α-AGM1 antibody-treated, were injected with α-GalCer or vehicle 24 h after NK cell depletion. 
As shown in Fig. 4, NK cell-depleted mice had similar responses to α-GalCer administration as control mice, 
showing an increase in liver weight at 24 h (Fig. 4A) as well as the biphasic changes in serum iron (Fig. 4B) and 
hepcidin mRNA expression (Fig. 4C). Indeed, while serum iron levels in both control and NK cell-depleted 
mice were reduced at 6 h and increased at 24 h, the hepcidin mRNA levels were conversely increased at 6 h and 
decreased at 24 h after α-GalCer treatment. Taken together, these results indicate that NK cells are not required 
for α-GalCer-induced disturbances in iron metabolism.
Role of Kupffer cells in α‑GalCer‑induced changes in iron metabolism. In addition to NK cells, 
Kupffer cells, the resident macrophages of the liver, are another likely cellular candidate that may contribute to 
α-GalCer-induced changes in iron metabolism as they produce vast amounts of IL-624. Since IL-6 plays a major 
role in hepcidin regulation during  inflammation25, we depleted Kupffer cells by pre-treating mice with clo-
dronate liposome (c-lip) and assessed the depletion efficiency by RT-PCR using primers for Kupffer cell markers, 
F4/80 and Clec4f. When compared to control mice treated with phosphate-buffered saline-liposomes (PBS-lip), 
both F4/80 and Clec4f mRNA expression were significantly reduced in c-lip-treated mice, demonstrating that 
c-lip induced an efficient deletion of Kupffer cells in the liver (Supplementary Fig. 2). Importantly, the propor-
tion and activation state of iNKT cells, as quantified by CD69 expression, was not influenced by c-lip treatment 
(Supplementary Fig.  3). PBS-lip-treated and c-lip-treated mice were subsequently challenged with α-GalCer 
treatment. Interestingly, the liver weights in both treatment groups were comparable and increased at 24 h post-
α-GalCer treatment (Fig. 5A). This result suggests that depletion of Kupffer cells is not sufficient to prevent liver 
enlargement driven by iNKT cell activation.
We further examined the impact of Kupffer cell depletion on iron metabolism. When compared to PBS-lip-
treated mice, c-lip-treatment alone (without α-GalCer treatment) resulted in significantly lower serum iron 
levels at 6 h but not at 24 h (Fig. 5B, comparison of vehicle treatment in PBS-lip and c-lip groups). This suggests 
that depletion of Kupffer cells per se has a transient impact on serum iron levels. Regardless, at 6 h following 
α-GalCer administration, serum iron levels decreased to a similar extent in both PBS-lip and c-lip treated mice 
(Fig. 5B), suggesting that Kupffer cells do not significantly contribute to the early phase of iron homeostasis dis-
ruption. At 24 h after α-GalCer-treatment, serum iron levels returned to normal levels in Kupffer cell-depleted 
mice injected with vehicle. However, α-GalCer treatment did not further elevate serum iron levels in Kupffer 
cell-depleted (c-lip-treated) mice relative to PBS-lip-treated mice. Altogether, these results suggest that Kupffer 
cells contribute to the maintenance of serum iron levels in the absence of acute stimulation and to the increase 
in serum iron levels following iNKT cell activation.
The acute hypoferremic response is accompanied by a strong induction of hepatic hepcidin mRNA 
 expression25. Accordingly, at 6 h after vehicle administration, hepcidin mRNA levels were increased in c-lip-
treated mice relative to PBS-lip treated mice, further supporting an impact of Kupffer cell deletion on iron metab-
olism in the absence of inflammatory challenge (i.e., without α-GalCer treatment, Fig. 5C). At 6 h post-α-GalCer 
treatment hepcidin mRNA levels were similarly increased in both PBS-lip- and c-lip-treated mice (Fig. 5C). 
Therefore, Kupffer cells do not contribute significantly to early changes in iron metabolism after α-GalCer 
treatment. In addition, hepcidin mRNA levels were similarly decreased at 24 h post-α-GalCer administration 
in both PBS-lip- and c-lip-treated mice (Fig. 5C). These results indicate that Kupffer cells are not essential for 
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Liver damage after α‑GalCer‑mediated iNKT activation. Our results so far indicate that biphasic 
changes in iron homeostasis induced by α-GalCer are mediated by iNKT cells. The iNKT cell-driven impact on 
iron homeostasis does not involve the activation of NK cells, whereas Kupffer cells contribute to the regulation 
Figure 2.  Iron metabolism changes induced by α-GalCer-mediated iNKT activation are abolished in CD1d−/− 
mice. Wild-type and CD1d−/−mice were injected with vehicle (CTL) or 100 μg/Kg body weight of α-GalCer. 
(A) Liver weight. (B) Serum iron. (C) Hepcidin mRNA expression. Each symbol represents one mouse with 
the bar indicating the mean; n = 8 per group. Statistical analysis was performed with one-way ANOVA. n.s., not 
significant compared to control mice (CTL) injected with vehicle.
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of serum iron levels and hepcidin expression in the absence of iNKT stimulation. In addition to inflammatory 
cytokine production, iNKT cells activated with α-GalCer can induce liver  damage26, which could explain par-
tially the increase in circulating and tissue iron levels. To quantify liver damage, we measured serum alanine 
aminotransferase (ALT) levels, which were elevated up to 24 h post-treatment with α-GalCer (Fig. 6A).
Figure 3.  Jα18−/− mice lacking Vα14 iNKT cells fail to respond to α-GalCer treatment and show no change 
in iron metabolism. Wild-type (Wt) and Jα18−/− mice were injected with vehicle or 100 μg/kg body weight of 
α-GalCer. (A) Liver weight 24 h post-treatment. (B) Serum iron at 6 h and 24 h post-treatment. (C) Hepcidin 
mRNA expression at 6 h and 24 h post-treatment. Each symbol represents one mouse with the bar indicating the 
mean; n = 8 per group. Statistical analysis was performed with one-way ANOVA. n.s. not significant compared to 
control mice injected with vehicle.
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Regulation of BMP/SMAD and STAT3 pathways after α‑GalCer‑mediated iNKT activa‑
tion. Regulation of hepcidin expression by iron involves signaling through the bone morphogenetic protein 
(BMP) and Sma- and Mad-related protein 4 (BMP/SMAD4) pathway that regulates hepcidin via the SMAD1, 
SMAD5, and SMAD8  proteins27. This iron-signaling pathway involves upregulation of BMPs, particularly 
 BMP628, in response to heightened iron  levels29,30. Hence, we next measured the levels of Bmp6 mRNA expres-
sion levels in response to α-GalCer acute treatment. Despite the rise in serum and tissue iron, Bmp6 mRNA 
levels substantially decreased as early as 6 h post-α-GalCer treatment (Fig. 6B).
Figure 4.  Iron metabolism changes induced by α-GalCer-mediated iNKT activation is independent of NK 
cells. Mice were injected with control isotype Ig (IgG) or with α-asialoGM1 antibodies before the administration 
of vehicle or 100 μg/Kg body weight of α-GalCer. (A) Liver weight 24 h post-treatment. (B) Serum iron at 6 h 
and 24 h post- α-GalCer treatment. (C) Hepcidin mRNA expression at 6 h and 24 h post- α-GalCer treatment. 
Each symbol represents one mouse with the bar indicating the mean; n = 6 per group. Statistical analysis was 
performed with one-way ANOVA.
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Once the BMP6/SMAD pathway is activated by iron, inhibitory SMADs, particularly SMAD7, are also 
 upregulated31. However, Smad7 mRNA levels were significantly suppressed after α-GalCer administration 
(Fig. 6B). This indicates that the lack of response to elevated iron levels was not due to an exaggerated expres-
sion of SMAD7, but that instead, Smad7 expression levels appeared to follow a general pattern of inhibition of 
BMP/SMAD signaling in response to α-GalCer.
To further confirm that hepcidin suppression in response to α-GalCer treatment was due to inhibition of the 
BMP/SMAD pathway, we assessed phosphorylation levels of SMAD1/5/8 in liver nuclear extracts. We found 
Figure 5.  Influence of Kupffer cells on the iron metabolism changes induced by α-GalCer-mediated iNKT 
activation. Mice were injected with PBS-liposomes or with clodronate-liposomes 48 h before the administration 
of vehicle or 100 μg/Kg body weight of α-GalCer. (A) Liver weight 24 h post-treatment. (B) Serum iron at 6 h 
and 24 h post- α-GalCer treatment. (C) Hepcidin mRNA expression at 6 h and 24 h post-α-GalCer treatment. 
Each symbol represents one mouse with the bar indicating the mean; n = 9–10 per group. Statistical analysis was 
performed with one-way ANOVA. n.s. not significant compared to control mice injected with vehicle.
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that SMAD1/5/8 phosphorylation was decreased at 6 h and 24 h post-α-GalCer treatment (Fig. 6C), confirming 
that the BMP/SMAD pathway was not activated in response to elevations in circulating and tissue iron induced 
by α-GalCer.
Hepcidin levels are additionally regulated by inflammatory cytokines, such as IL-6, via the signal transducer 
and activator of transcription 3 (STAT3)  pathway32. Accordingly, we found that at 6 h but not at 24 h post-
treatment, STAT3 phosphorylation was enhanced, which was consistent with hepcidin induction during the 
early phase (Fig. 6C). Overall, these data indicate that at earlier stages after iNKT activation, STAT3 signaling is 
enhanced while BMP/SMAD signaling is suppressed. The outcome of these opposing signals of Hamp induction 
via STAT3 phosphorylation vs. Hamp inhibition via BMP/SMAD suppression, is the activation of Hamp expres-
sion via the inflammatory, STAT3-mediated pathway. In contrast, inhibition of the BMP/SMAD signaling path-
way predominates at the stage when STAT3 activation ceases, and consequently Hamp expression is repressed.
α‑GalCer treatment induces immune cell proliferation in the liver and spleen. To further under-
stand the increase in total liver iron induced by α-GalCer treatment (Fig. 1B), we measured circulating and liver 
ferritin levels. Serum ferritin levels increased at 6 h, followed by a significant decrease starting at 48 h to day 
3, while liver ferritin levels followed a similar kinetic by increasing with a slight delay at 24 h and significantly 
decreasing at 72 h (Fig. 7A). Ferric iron staining of liver samples by DAB-enhanced Perl’s Prussian blue showed a 
Figure 6.  Liver damage induced by α-GalCer and inhibition of BMP/SMAD signaling pathway. Wild-type mice 
were injected with vehicle (indicated by the gray area across the graphs) or 100 μg/Kg body weight of α-GalCer. 
(A) Liver alanine aminotransferase levels. (B) Bmp6 and Smad7 mRNA expression in the liver. (C) Liver nuclear 
extracts analyzed by western blotting. Upper blots: phosphorylated SMAD1/5/8 (pSMAD1/5/8) and total 
SMAD1/5/8; Lower blots: phosphorylated STAT3 (pSTAT3) and total STAT3.The full-length blots are presented 
in Supplementary Fig. 6. Data in (A) and (B) are presented as mean ± SEM for a minimum of n = 12 mice per 
time point. Statistical analysis was performed with one-way ANOVA. *,†P < 0.01, compared to mice injected with 
vehicle at each time point.
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similar distribution pattern (Supplementary Fig. 4). These results indicate that the extra iron in the liver was not 
being stored in ferritin or hemosiderin. Since iron is required for DNA synthesis in proliferating  cells33, where it 
would not be stored in ferritin, we directly assessed the levels of CD71 or transferrin receptor (TfR) on mononu-
clear cells isolated from the liver and spleen using flow cytometry. The percentage of cells expressing CD71 was 
significantly elevated at 24 h in the liver and at 72 h in the spleen (Fig. 7B). These data suggest that immune cells 
were increasing their ability to uptake iron for proliferation rather than for storage into ferritin.
α-GalCer treatment induces activation and proliferation of iNKT  cells14,15. These activated iNKT cells pro-
duce cytokines, which lead to the recruitment, activation and proliferation of other immune  cells16,17. Indeed, 
we found that at day 3, the proportion and absolute number of iNKT cells was significantly increased in the liver 
of α-GalCer-treated mice relative to controls (Supplementary Fig. 5). In line with this increase in number, we 
found that iNKT cells were actively proliferating, as quantified by the expression of Ki-67 (Fig. 7C,D). The acti-
vation of iNKT cells also resulted in the proliferation of other immune cells. Using CD45 to identify all immune 
cells, we noted an increase in the Ki-67 proliferation marker as early as 6 h following α-GalCer administration 
(Fig. 7C,D). Whereas B cell proliferation was modestly increased, T cell proliferation was significantly induced 
in both the liver and the spleen (Fig. 7C,D). Overall, α-GalCer-mediated activation of iNKT cells induced sub-
stantial immune cell proliferation in both the liver and spleen. Notably, the proliferation was more prominent 
in the liver, where iNKT cells are most abundant.
Discussion
The aim of this study was to investigate the influence of activated iNKT cells on iron homeostasis. Our work sug-
gests that iNKT activation has particular effects in iron homeostasis that could be relevant for treatments aimed 
at regulating hepcidin expression. A possible role for iNKT cells in modifying iron metabolism is suggested by 
their ability to secrete cytokines upon activation, and by their predominant location in mouse liver, where the 
major regulator of iron homeostasis, hepcidin, is produced. Hepcidin regulates systemic iron homeostasis via the 
hepcidin/ferroportin axis, as it binds to ferroportin 1 and induces ferroportin internalization and  degradation34. 
Decreased ferroportin levels result in lowering intestinal iron absorption and iron export from macrophages 
and Kupffer cells, which are responsible for iron recycling. Therefore, hepcidin levels are tightly regulated by 
Figure 7.  Serum and liver ferritin changes and immune cell proliferation induced by α-GalCer. Wild-type 
mice were injected with vehicle or 100 μg/Kg body weight of α-GalCer. (A) Serum and liver ferritin levels. 
(B) Transferrin receptor (CD71) expression within mononuclear cells isolated from liver and spleen. (C) 
Proliferating cells in the liver. (D) Proliferating cells in the spleen. Data are presented as mean ± SEM for a 
minimum of n = 3–6 mice per time point. Statistical analysis was performed with one-way ANOVA. *P < 0.05, 
compared to mice injected with vehicle.
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inflammation, anaemia, hypoxia, and iron  levels35, and the mechanisms that are involved overlap to control 
immune responses, prevent iron toxicity, and respond to changes in erythropoietic  demand36. Here, we show 
that α-GalCer-mediated iNKT cells activation in vivo results in biphasic changes in systemic iron homeostasis.
The changes in iron metabolism triggered by α-GalCer were abolished in CD1d−/− mice. Since α-GalCer is a 
highly specific ligand for CD1d, this rules out possible unspecific effects, including those unrelated to antigen 
presentation. This also highlights a specific role for iNKT cells, confirmed by the lack of response in Jα18−/− mice. 
Indeed, while CD1d−/− mice lack all NKT cell subsets, Jα18−/− mice are specifically devoid of Vα14 iNKT  cells21. 
Interestingly, iron in turn may influence iNKT levels, as shown in patients with hereditary hemochromatosis, an 
iron overloading disease. These individuals show a decrease in iNKT cells that is more pronounced in patients 
with higher iron  levels37. Finally, using anti-asialoGM1 antibodies, we ruled out a role for NK cells, which 
undergo proliferation and activation after α-GalCer administration.
Kupffer cells, the resident macrophages of the liver, have been historically studied in regard to iron metabolism 
as they are major producers of pro-inflammatory cytokines. In addition, Kupffer cells and macrophages play 
a fundamental role in iron recycling after  erythrophagocytosis38. In our study, c-lip depletion of Kupffer cells 
alone significantly altered iron homeostasis, as shown by a decrease in serum iron accompanied by increased 
hepcidin expression. Similar effects after Kupffer cell depletion have been previously  reported39. We demonstrate 
that these changes are not due to secondary activation of iNKT cells following Kupffer cell depletion. In addition, 
our depletion experiments demonstrated that Kupffer cells are dispensable for α-GalCer-induced modulation of 
hepcidin. Our findings support and add to previous work by others, which demonstrated that Kupffer cells do 
not play a role in regulating hepcidin expression in response to  inflammation39,40 and  iron39–41.
We followed iron-related parameters after a single injection of α-GalCer to activate iNKT cells in C57BL/6 
wild-type mice. Upon injection of α-GalCer, an early response was observed with decreases in serum iron, trans-
ferrin saturation, and Fp1 expression, while hepcidin expression increased. These early responses are similar to 
the changes observed upon lipopolysaccharide injection, which are attributed to inflammatory  cytokines32,42 and 
are consistent with the well-documented ability of activated NKT cells to rapidly release copious amounts of the 
proinflammatory cytokines IFN-γ, TNF-α, and IL-6 in circulation and in the  liver43,44. Accordingly, we observed 
an increase in STAT3 phosphorylation at 6 h post-treatment. This may explain the parallel induction of hepci-
din at this early phase, as STAT3 activation has been shown to induce hepatic hepcidin expression in response 
to  inflammation32. Interestingly, at the same 6 h time point, SMAD1/5/8 phosphorylation was downregulated, 
which would downregulate hepcidin expression towards hepcidin suppression. This agrees with previous work 
showing that the level of hepcidin expression levels in the presence of opposing signaling is determined by the 
strength of the individual stimuli which, in our study, is the upregulation of STAT3  phosphorylation36.
A second phase following α-GalCer treatment involved a rise in tissue and serum iron levels but, paradoxi-
cally, hepcidin levels were strongly inhibited. The increase in circulating and tissue iron levels may be partially 
due to liver damage, since administration of α-GalCer to mice has been shown to induce immune-mediated 
liver injury and cell  death26 that may be accompanied by iron release from dying cells. Our results corroborate 
these earlier studies, based on our observation of elevated serum ALT levels that peaked between 12 and 24 h 
post-treatment. Alternatively, or concomitantly, Kupffer cell may also be involved in the increase in serum iron 
levels, since their depletion seemed to abolish the serum iron surge at 24 h.
The rise in iron levels would be expected to modulate hepcidin levels by inducing its expression, as found in 
mice treated with iron-enriched  diets6,45,46 or injected with iron-dextran6. At 24 h after acute α-GalCer treatment, 
STAT3 phosphorylation returned to normal. Hence, non-inflammatory pathways regulate hepcidin expression at 
the later stage/second phase. The iron-sensing pathway initiates a sequence that starts with an increase in BMP 
levels, notably  BMP630,47, binding to BMP receptors, followed by activation of SMAD1/5/8/phosphorylation47 
and binding to  SMAD448. The resulting SMAD complex translocates into the nucleus and binds to the BMP 
responsive element in the Hamp promoter  region49.
Previous studies demonstrated that both circulating and tissue iron activate the BMP/SMAD signaling path-
way to modulate hepcidin expression, albeit targeting different levels of the  pathway29. While elevation of liver 
iron levels induces hepatic expression of Bmp6 in the liver, increased transferrin saturation activates SMAD1/5/8 
phosphorylation downstream of BMP6. Intriguingly, in mice treated with α-GalCer, liver Bmp6 levels were 
strongly suppressed, and SMAD1/5/8/phosphorylation did not increase despite elevated levels of circulating iron. 
This suggests that the inhibition of hepcidin mRNA expression is related to a lack of activation of the BMP6/
SMAD pathway in response to elevated circulating iron. In our setting, Smad7 expression was also significantly 
suppressed, ruling out a possible activation of inhibitory SMAD7, which functions as a feedback inhibitor of 
the BMP/SMAD  pathway31. In addition, inhibitory SMAD7 was previously shown to follow the overall activa-
tion of the SMAD1/5/8 signaling pathway and thus, was significantly modulated by both acute and chronic iron 
 administration29. Therefore, downregulation of Smad7 expression in our studies further supports the view that 
α-GalCer suppressed hepcidin expression via inhibition of the BMP6/SMAD pathway.
A decrease of hepatic Bmp6 mRNA levels in the presence of heightened liver iron has also been described in 
conditional knockout models of the iron exporter  ferroportin50. These mouse models showed decreased Bmp6 
expression and phosphorylated SMAD1/5/8 as well as decreased expression of Hamp in the liver, despite elevated 
liver iron loads. The investigators attributed the decrease in Bmp6 mRNA to a liver-independent signal generated 
in response to high iron demand for erythropoiesis. In our study, we show that α-GalCer strongly stimulates the 
proliferation of immune cells, including NKT, B and T lymphocytes, as shown by  others18,19,26. Moreover, lympho-
cytes are known to increase the synthesis and expression of surface TfR in response to the increased iron demand 
during  proliferation51. Accordingly, we also show a significant increase in cells expressing TfR, consistent with 
the need to increase transferrin uptake to provide iron for fundamental cellular processes, especially for DNA 
 synthesis33. Heightened iron demand to support immune cell proliferation in response to α-GalCer may partially 
explain the inhibition of the BMP/SMAD pathway and, consequently, the downregulation of Hamp expression.
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In summary, the present work describes the effects of α-GalCer on iron homeostasis and demonstrates that 
iNKT cells are essential for α-GalCer effects. Activation of iNKT cells in vivo triggers substantial immune cell 
proliferation that translated into increased iron demand, contributing to a disassociation between temporary rises 
in circulating and tissue iron, and a marked suppression of hepcidin expression in the liver via inhibition of the 
BMP/SMAD pathway. Altogether, our findings suggest that the iNKT/CD1d system plays an important role in 
iron homeostasis and that modulation of the iNKT/CD1d pathway may be useful to regulate hepcidin expression.
Methods
Mice. This study was carried out in accordance with Canadian Council on Animal Care guidelines. The 
protocol was evaluated and approved by the institutional Animal Care Committee of the CRCHUM (“Supple-
mentary methods”). C57BL/6 wild-type (Wt), and CD1d−/− (C57BL/6 background) mice, were purchased from 
Jackson Laboratories (Bar Harbor, ME). Mice deficient in iNKT cells (Jα18−/− mice) were kindly provided by 
Dr. Taniguchi (Kanagawa, Japan)21 and were backcrossed at least 10 times to C57BL/6 (Dr. Thierry Mallevaey, 
University of Toronto, Canada)52.
Measurement of serum iron, transferrin saturation, ALT, and tissue iron concentration. Serum 
iron, total iron‐binding capacity, transferrin saturation, and ALT were assessed via colorimetric assay with the 
Kodak Ektachem DT60 system (Johnson & Johnson, Ortho Clinical Diagnostics, Mississauga, ON). Spleen and 
liver iron concentrations were assessed by acid digestion of tissue samples, followed by iron quantification with 
atomic absorption  spectroscopy53.
In vivo activation of iNKT cells. Mice received one injection of 100 μg/kg body weight of α-GalCer (Enzo 
Life Sciences Inc., Farmingdale, NY) diluted in Dulbecco’s modified eagle medium (DMEM) (Wisent Inc., St-
Bruno, Québec, Canada). Control mice received a corresponding dose of vehicle.
NK and Kupffer cell depletion. NK cells were depleted by intraperitoneal injection of 500 μg anti-asialo 
GM1 antibody (α-AGM1; Wako Chemicals, Richmond, VA, USA) diluted in PBS, 24 h before α-GalCer treat-
ment. Control mice were injected on the same days with 500 μg control rabbit Ig (Jackson ImmunoResearch, 
West Grove, PA, USA). To deplete Kupffer cells, 200 μL of clodronate liposome suspension (c-lip; 5 mg/ml; Clo-
dronateLiposomes.org, Haarlem, The Netherlands) or of PBS encapsulated liposomes (PBS-lip) as control, was 
injected intravenously into the mice 48 h before administration of α-GalCer54,55.
Confirmation of NK and Kupffer cells depletion. Depletion of NK cells was confirmed by analyses of 
liver mononuclear cells stained with anti-NK1.1 phycoerythrin-conjugated monoclonal antibody (mAb) and 
anti-CD3 Alexa fluor-conjugated mAb (both from PharMingen, San Diego, CA), followed by flow cytometry as 
previously  described45. Samples were analyzed using an LSRFortessa flow cytometer (BD Biosciences) and the 
data were analyzed using FlowJo software (BD Biosciences).
Kupffer cell depletion was confirmed by quantitative RT-PCR in liver samples using primers for HPRT-1, 
F4/80 as a representative surface marker of mouse mononuclear  phagocytes56, and Clec4f, a specific marker of 
Kupffer  cells57.
Measuring iNKT cell proportion and activation following c‑lip treatment. Livers were perfused 
with cold PBS followed by a solution of 1 mg/ml of collagenase type V (Sigma). Livers were then harvested, cut 
into small pieces and incubated with 5 ml of collagenase type V for 20 min at 37 °C. The enzymatic digestion 
was stopped with ice cold media containing 10% fetal calf serum. The liver was pressed through a 70 µm cell 
strainer. The cell suspension was washed, and lymphocytes were separated on a 33.3% Percoll density gradient. 
Spleens were harvested and pressed through a 70 µm cell strainer. Both cell suspensions from liver and spleen 
were treated with an  NH4Cl solution to lyse red blood cells. Single cell suspensions of liver and spleen were 
counted on a hemacytometer using trypan blue. To quantify iNKT cells and determine their activation status, 
cells were stained with the following reagents from Biolegend unless otherwise specified: Viability dye (Zombie 
Aqua™), CD45 PerCP-Cy5.5 (RA3-6B2), CD3 BV711 (17A2), CD19 Alexa-Fluor 700 (6D5), PBS57-coupled 
CD1d tetramer Pacific Blue (NIH tetramer core facility), CD69 APC (H1.2F3), CD335 PE (29A1.4, eBiosci-
ence), and NK1.1 BV605 (PK136). The samples were acquired on BD FACSCelesta and analysed with FlowJo 
LLC software version 10 (BD Biosciences). iNKT cells were defined as  CD45+  CD19−  CD3+ CD1d-tetramer+ 
 CD335− NK1.1+ cells. The percentage of  CD69+ cells among iNKT cells reflects the activation status. Dead cells 
and doublets were excluded from the analyses.
Measuring immune cell proportion and proliferation following αGal‑Cer treatment. At the 
indicated time points, single cell suspensions of livers and spleens were prepared as described above. To quan-
tify cell proliferation, cells were stained with the same combination of antibodies used to identify iNKT cells in 
addition to Ki-67 FITC (B56, BD Biosciences). As a measure of proliferation, the percentage of Ki-67+ cells was 
quantified on total hematopoietic cells (CD45+), T cells  (CD45+  CD3+  CD19−), B cells  (CD45+CD3−CD19+) and 
iNKT cells  (CD45+  CD19−  CD3+ CD1d-tetramer+ NK1.1+). To quantify TfR expression, cells were stained with 
the CD71 FITC antibody (C2, BD Biosciences). The samples were acquired on BD FACSCelesta and analysed 
with FlowJo LLC software version 10 (BD Biosciences). Dead cells and doublets were excluded from the analyses.
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Quantitative RT‑PCR. Total RNA was isolated with Trizol reagent (Invitrogen, Burlington, ON), and 
reverse transcription was performed with the Omniscript RT kit (QIAGEN, Mississauga, ON). mRNA expres-
sion levels were measured by real-time PCR in a Rotor Gene 3000 Real Time DNA Detection System (Mon-
treal Biotech, Kirkland, QC) with QuantiTect SYBRGreen I PCR kits (QIAGEN, Mississauga, ON) as previously 
 described53. Expression levels were normalized to the housekeeping gene β-actin (Actb). Primers are listed in 
Supplementary Table 1.
SDS–PAGE and Western blot analysis. SDS–PAGE and western blot analysis were performed on liver 
nuclear  extracts36. Livers were removed, rinsed in ice-cold PBS, and used to prepare liver nuclear extracts with 
Nuclear Extract Kits (Active Motif, Carlsbad, CA). Nuclear protein extracts were separated by 10% SDS–PAGE 
gel and blotted onto nitrocellulose membranes (GE Healthcare, Little Chalfont, United Kingdom). The mem-
branes were immunoblotted with the following antibodies: phospho-STAT3, STAT3, phospho-SMAD1/5/8 (Cell 
Signaling, catalogue #9511S, Danvers, MA), SMAD1/5/8 (Santa Cruz Biotechnology, catalogue #SC-6031-R, 
Santa Cruz, CA) and β-actin (Abcam, Cambridge, MA). As a secondary antibody, anti–rabbit IgG (Cell Signal-
ing) or anti–mouse IgG (GE Healthcare) were used. Antigen–antibody complexes were visualized with the ECL 
Western Blotting Detection Reagent (GE Healthcare) in x-ray film. Films were digitalized using a scanner (HP 
psc2350, 300 dpi resolution), and obtained JPEG images were imported into Adobe Illustrator (300 dpi) and 
assembled.
Serum and liver ferritin assay. Ferritin was measured with an ELISA kit as per manufacturer’s instruc-
tions for serum (mouse Ferritin Light chain ELISA kit, Kamiya Biomedical, Seattle, USA) and for liver homoge-
nates (mouse Ferritin Heavy chain ELISA kit, Kamiya Biomedical).
Histology. Liver tissue sections were stained with DAB-enhanced Perl’s Prussian blue for ferric iron detec-
tion (iron stain kit; Sigma Immunochemicals).
Statistical analysis. All statistics were calculated with Prism software (GraphPad, San Diego, CA), with a 
pre-specified significant P-value of 0.05. Data were pooled from two or three independent experiments. Multiple 
comparisons were evaluated statistically by one-way analysis of variance (ANOVA) followed by the Bonferroni 
multiple comparison test.
Received: 12 May 2020; Accepted: 19 November 2020
References
 1. Weiss, G., Ganz, T. & Goodnough, L. T. Anemia of inflammation. Blood 133, 40–50. https ://doi.org/10.1182/blood -2018-06-85650 
0 (2019).
 2. Weiss, G. Iron metabolism in the anemia of chronic disease. Biochim. Biophys. Acta 1790, 682–693 (2009).
 3. Andrews, N. C. Anemia of inflammation: The cytokine-hepcidin link. J. Clin. Invest 113, 1251–1253 (2004).
 4. Hentze, M. W., Muckenthaler, M. U., Galy, B. & Camaschella, C. Two to tango: Regulation of Mammalian iron metabolism. Cell 
142, 24–38. https ://doi.org/10.1016/j.cell.2010.06.028 (2010).
 5. Park, C. H., Valore, E. V., Waring, A. J. & Ganz, T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 
276, 7806–7810 (2001).
 6. Pigeon, C. et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is 
overexpressed during iron overload. J. Biol. Chem. 276, 7811–7819 (2001).
 7. Kubes, P. & Jenne, C. Immune responses in the liver. Annu. Rev. Immunol. 36, 247–277. https ://doi.org/10.1146/annur ev-immun 
ol-05111 6-05241 5 (2018).
 8. Eberl, G. et al. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. J. Immunol. 162, 6410–6419 
(1999).
 9. Nishimura, T. et al. The interface between innate and acquired immunity: Glycolipid antigen presentation by CD1d-expressing 
dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int. Immunol. 12, 987–994. 
https ://doi.org/10.1093/intim m/12.7.987 (2000).
 10. Matsuda, J. L. et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192, 
741–754 (2000).
 11. Zeissig, S. et al. CD1d-restricted pathways in hepatocytes control local natural killer T cell homeostasis and hepatic inflammation. 
Proc. Natl. Acad. Sci. USA 114, 10449–10454. https ://doi.org/10.1073/pnas.17014 28114 (2017).
 12. Huh, J. Y. et al. Deletion of CD1d in adipocytes aggravates adipose tissue inflammation and insulin resistance in obesity. Diabetes 
66, 835–847. https ://doi.org/10.2337/db16-1122 (2017).
 13. Luc, V. K. NKT cells: T lymphocytes with innate effector functions. Curr. Opin. Immunol. 19, 354–364 (2007).
 14. Taniguchi, M., Tashiro, T., Dashtsoodol, N., Hongo, N. & Watarai, H. The specialized iNKT cell system recognizes glycolipid 
antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. Int. Immunol. 22, 
1–6. https ://doi.org/10.1093/intim m/dxp10 4 (2010).
 15. Choi, J., Rudak, P. T., Lesage, S. & Haeryfar, S. M. M. Glycolipid stimulation of invariant NKT cells expands a unique tissue-resident 
population of precursors to mature NK Cells endowed with oncolytic and antimetastatic properties. J. Immunol. 203, 1808–1819. 
https ://doi.org/10.4049/jimmu nol.19004 87 (2019).
 16. De Domenico, I. et al. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses 
in mice. J. Clin. Invest. 120, 2395–2405 (2010).
 17. Natori, T., Morita, M., Akimoto, K. & Koezuka, Y. Agelasphins, novel antitumor and immunostimulatory cerebrosides from the 
marine sponge Agelas mauritianus. Tetrahedron 50, 2771–2784. https ://doi.org/10.1016/S0040 -4020(01)86991 -X (1994).
 18. Eberl, G. & MacDonald, H. R. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur. J. Immunol. 
30, 985–992. https ://doi.org/10.1002/(sici)1521-4141(20000 4)30:4%3c985 ::aid-immu9 85%3e3.0.co;2-e (2000).
13
Vol.:(0123456789)
Scientific Reports |        (2020) 10:21026  | https://doi.org/10.1038/s41598-020-78037-3
www.nature.com/scientificreports/
 19. Eberl, G., Brawand, P. & MacDonald, H. R. Selective bystander proliferation of memory  CD4+ and  CD8+ T cells upon NK T or T 
cell activation. J. Immunol. 165, 4305–4311. https ://doi.org/10.4049/jimmu nol.165.8.4305 (2000).
 20. Bendelac, A. et al. CD1 recognition by mouse NK1+ T lymphocytes. Science 268, 863–865 (1995).
 21. Cui, J. et al. Requirement for Va14 NKT cells in IL-12-mediated rejection of tumors. Science 278, 1623–1626. https ://doi.
org/10.1126/scien ce.278.5343.1623 (1997).
 22. Carnaud, C. et al. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. 
Immunol. 163, 4647–4650 (1999).
 23. Kasai, M. et al. In  vivo effect of anti-asialo GM1 antibody on natural killer activity. Nature 291, 334–335. https ://doi.
org/10.1038/29133 4a0 (1981).
 24. Decker, K. Biologically active products of stimulated liver macrophages (Kupffer cells). Eur. J. Biochem. 192, 245–261. https ://doi.
org/10.1111/j.1432-1033.1990.tb192 22.x (1990).
 25. Nemeth, E. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. 
J. Clin. Invest. 113, 1271–1276. https ://doi.org/10.1172/JCI20 945 (2004).
 26. Osman, Y. et al. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. 
Eur. J. Immunol. 30, 1919–1928. https ://doi.org/10.1002/1521-4141(20000 7)30:7%3c191 9::Aid-immu1 919%3e3.0.Co;2-3 (2000).
 27. Babitt, J. L. et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet. 38, 531–539 
(2006).
 28. Andriopoulos, B. Jr. et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat. Genet. 41, 
482–487. https ://doi.org/10.1038/ng.335 (2009).
 29. Corradini, E. et al. Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway 
in mice. Hepatology (Baltimore, MD) 54, 273–284. https ://doi.org/10.1002/hep.24359 (2011).
 30. Kautz, L. et al. Iron overload induces BMP6 expression in the liver but not in the duodenum. Haematologica 96, 199–203. https ://
doi.org/10.3324/haema tol.2010.03196 3 (2011).
 31. Mleczko-Sanecka, K. et al. SMAD7 controls iron metabolism as a potent inhibitor of hepcidin expression. Blood 115, 2657–2665. 
https ://doi.org/10.1182/blood -2009-09-23810 5 (2010).
 32. Wrighting, D. M. & Andrews, N. C. Interleukin-6 induces hepcidin expression through STAT3. Blood 108, 3204–3209. https ://
doi.org/10.1182/blood -2006-06-02763 1 (2006).
 33. Puig, S., Ramos-Alonso, L., Romero, A. M. & Martínez-Pastor, M. T. The elemental role of iron in DNA synthesis and repair. 
Metallomics 9, 1483–1500. https ://doi.org/10.1039/C7MT0 0116A (2017).
 34. Nemeth, E. et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 
2090–2093. https ://doi.org/10.1126/scien ce.11047 42 (2004).
 35. Papanikolaou, G. & Pantopoulos, K. Systemic iron homeostasis and erythropoiesis. IUBMB Life 69, 399–413. https ://doi.
org/10.1002/iub.1629 (2017).
 36. Huang, H., Constante, M., Layoun, A. & Santos, M. M. Contribution of STAT3 and SMAD4 pathways to the regulation of hepcidin 
by opposing stimuli. Blood 113, 3593–3599. https ://doi.org/10.1182/blood -2008-08-17364 1 (2009).
 37. Maia, M. L. et al. Invariant natural killer T cells are reduced in hereditary hemochromatosis patients. J. Clin. Immunol. 35, 68–74. 
https ://doi.org/10.1007/s1087 5-014-0118-0 (2015).
 38. Sukhbaatar, N. & Weichhart, T. Iron regulation: Macrophages in control. Pharmaceuticals 11, 137 (2018).
 39. Theurl, M. et al. Kupffer cells modulate iron homeostasis in mice via regulation of hepcidin expression. J. Mol. Med. 86, 825. https 
://doi.org/10.1007/s0010 9-008-0346-y (2008).
 40. Lou, D.-Q. et al. Iron- and inflammation-induced hepcidin gene expression in mice is not mediated by Kupffer cells in vivo. 
Hepatology (Baltimore, MD) 41, 1056–1064. https ://doi.org/10.1002/hep.20663 (2005).
 41. Montosi, G. et al. Kupffer cells and macrophages are not required for hepatic hepcidin activation during iron overload. Hepatology 
(Baltimore, MD) 41, 545–552. https ://doi.org/10.1002/hep.20620 (2005).
 42. Falzacappa, M. V. V. et al. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 109, 353–358. 
https ://doi.org/10.1182/blood -2006-07-03396 9 (2007).
 43. Cao, Z. et al. A critical role for IFN regulatory factor 1 in NKT cell-mediated liver injury induced by α-galactosylceramide. J. 
Immunol. 185, 2536–2543. https ://doi.org/10.4049/jimmu nol.10000 92 (2010).
 44. Bendelac, A., Savage, P. B. & Teyton, L. The biology of NKT cells. Annu. Rev. Immunol. 25, 297–336 (2007).
 45. Makui, H., Soares, R. J., Jiang, W., Constante, M. & Santos, M. M. Contribution of Hfe expression in macrophages to the regulation 
of hepatic hepcidin levels and iron loading. Blood 106, 2189–2195 (2005).
 46. Mazur, A. et al. Dietary iron regulates hepatic hepcidin 1 and 2 mRNAs in mice. Metabolism 52, 1229–1231. https ://doi.org/10.1016/
S0026 -0495(03)00277 -4 (2003).
 47. Kautz, L. et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad 7, Id1, and Atoh8 in the mouse 
liver. Blood 112, 1503–1509. https ://doi.org/10.1182/blood -2008-03-14335 4 (2008).
 48. Wang, R. H. et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2, 
399–409. https ://doi.org/10.1016/j.cmet.2005.10.010 (2005).
 49. Casanovas, G., Mleczko-Sanecka, K., Altamura, S., Hentze, M. W. & Muckenthaler, M. U. Bone morphogenetic protein (BMP)-
responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD. J. Mol. 
Med. 87, 471–480. https ://doi.org/10.1007/s0010 9-009-0447-2 (2009).
 50. Zhang, Z. et al. Bmp6 expression can be regulated independently of liver iron in mice. PLoS ONE 9, e84906. https ://doi.org/10.1371/
journ al.pone.00849 06 (2014).
 51. Seligman, P. A., Kovar, J. & Gelfand, E. W. Lymphocyte proliferation is controlled by both iron availability and regulation of iron 
uptake pathways. Pathobiology 60, 19–26. https ://doi.org/10.1159/00016 3692 (1992).
 52. Mallevaey, T. et al. Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response 
during murine schistosomiasis. Infect. Immun. 75, 2171–2180. https ://doi.org/10.1128/iai.01178 -06 (2007).
 53. Layoun, A., Samba-Mondonga, M., Fragoso, G., Calve, A. & Santos, M. M. MyD88 adaptor protein is required for appropriate 
hepcidin induction in response to dietary iron overload in mice. Front. Physiol. 9, 159. https ://doi.org/10.3389/fphys .2018.00159 
(2018).
 54. Van Rooijen, N., Kors, N., Ende, M. V. D. & Dijkstra, C. D. Depletion and repopulation of macrophages in spleen and liver of rat 
after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate. Cell Tissue Res. 260, 215–222. https 
://doi.org/10.1007/BF003 18625 (1990).
 55. Yamamoto, T. et al. Repopulation of murine Kupffer cells after intravenous administration of liposome-encapsulated dichloro-
methylene diphosphonate. Am. J. Pathol. 149, 1271–1286 (1996).
 56. Austyn, J. M. & Gordon, S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur. J. Immunol. 
11, 805–815. https ://doi.org/10.1002/eji.18301 11013 (1981).
 57. Yang, C.-Y. et al. CLEC4F is an inducible C-type lectin in F4/80-positive cells and is involved in alpha-galactosylceramide presenta-
tion in liver. PLoS ONE 8, e65070. https ://doi.org/10.1371/journ al.pone.00650 70 (2013).
14
Vol:.(1234567890)
Scientific Reports |        (2020) 10:21026  | https://doi.org/10.1038/s41598-020-78037-3
www.nature.com/scientificreports/
Acknowledgements
This work was supported by grants from the Canadian Institutes of Health Research (CIHR, Grant no. PJT-
159775) and Natural Sciences and Engineering Research Council of Canada (NSERC, Grant RGPIN-2018-
06442) to MMS. HH received a PhD scholarship from the NSERC. SL is a Research Scholars Emeritus awardee 
from the FRQS. We wish to thank Dr. Taniguchi (Kanagawa, Japan) and Dr. Thierry Mallevaey (University of 
Toronto, Canada) for providing us with Jα18−/− mice. We also thank Dr. Mary Stevenson for a critical review of 
the manuscript prior to submission. We thank Jacqueline Chung for editing the manuscript.
Author contributions
H.H., V.Z.L., G.F., A.C., T.A.H., M.O., G.C.R., V.M.D. and M.M.S. contributed to the investigation, validation, 
methodology, and formal analysis. H.H. and M.M.S. contributed to conceptualization, data visualization and 
supervision. V.Z.L., S.L. and M.M.S. reviewed and edited the original draft. M.M.S. additionally contributed to 
resources and funding acquisition of the study. All authors have read and approved the version to be published.
Competing interests 
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https ://doi.org/10.1038/s4159 8-020-78037 -3.
Correspondence and requests for materials should be addressed to M.M.S.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2020
